Vast preclinical and clinical evidence has made angiogenesis one of the hallmarks of cancer. In many human tumours, vascular endothelial growth factor (VEGF) has been identified as the crucial mediator of this process. Initial studies suggested that angiogenesis, and VEGF in particular, could be inhibited without the risk of major side effects. After the pivotal data in first-line studies in patients with colorectal cancer, numerous clinical trials have been undertaken in patients with breast cancer. This review attempts to update these investigations and define the role of anti-VEGF antibody treatment in advanced breast cancer.
Baar, J., Silverman, P., Lyons, J., Fu, P., Abdul-Karim, F., Ziats, N. et al. (2009) A vasculature-targeting regimen of preoperative docetaxel with or withot bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res15: 3583-3590.
2.
Benoy, I.H., Salgado, R., Elst, H., van Dam, P., Weyler, J., van Marck, E. et al. (2005) Relative microvessel artea of the primary tumor, and not lymph node status predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer. Breast Cancer Res7: R210-R219.
3.
Bhargava, P.(2009) VEGF kinase inhibitors: how do they cause hypertension? Am J Physiol Reg Integr Comp Physiol297: R1-R5.
4.
Bluff, J.E., Menakuru, S.R., Cross, S.S., Higham, S.E., Balasubramanian, S.P., Brozwn, N.J. et al. (2009) Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease. Br J Cancer101: 666-672.
5.
Borre, M., Offersen, B.V., Nerstrom, B. and Overgaard, J. ( 1998) Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer78: 940-944.
6.
Burstein, H.J., Chen, Y.H., Parker, L.M., Savoie, J., Younger, J., Kuter, I. et al. (2008) VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res14: 7871-7877.
7.
Burstein, H.J., Spigel, D., Kindsvogel, K., Parker, L.M., Bunnel, C.A., Partridge, A.H. et al. (2005) Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II trial. Breast Cancer Res Treat94(Suppl. 1): S6 (Abstract 4).
8.
Calleri, A., Bono, A., Bagnardi, V., Quarna, P., Mancuso, P., Rabascio, C. et al. (2009) Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res15: 7652-7657.
9.
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M. et al. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature380: 435-439.
Cobleigh, M.A., Langmuir, V.K., Sledge, G.W., Miller, K.D., Haney, L., Novotny, W.F. et al. (2003) A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Sem Oncol30: 117-124.
12.
Conlin, A.K., Hudis, C.A., Bach, A., Moynahan, M., Lake, D., Forero-Torres, A. et al. (2009) Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer. J Clin Oncol27: 42s (Abstract 1006).
13.
Dellapasqua, S., Bertolini, F., Bagnardi, V., Campagnoli, E., Scarano, E., Torrisi, R. et al. (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol26: 4899-4905.
14.
Dhakal, H.P., Naume, B., Synnestvedt, M., Borgen, E., Kaaresen, R. and Schlichting, E. ( 2008) Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination. Clin Cancer Res14: 2341-2350.
15.
Dirix, L.Y., Romieu, G., Provencher, L., Grimes, D., de Souza Viana, L., Paterson, A. et al. (2009) Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study. Cancer Res69(Suppl.): 292s (Abstract #4116).
16.
Dirix, L.Y., Vermeulen, P.B., De Wever, I. and Van Oosterom, A.T. ( 1997) Soft tissue sarcoma in adults. Curr Opin Oncol9: 348-359.
17.
Dome, B., Hendrix, M.J.C., Paku, S., Tovari, J. and Timar, J. ( 2007) Alternative vascularization mechanisms in cancer. Am J Pathol170: 1-15.
18.
Eremina, V., Jefferson, J.A., Kowalewska, J., Hochster, H., Haas, M., Weisstuch, J. et al. (2008) VEGF inhibition and renal thrombotic microangiopathy . N Eng J Med358: 1129-1136.
19.
Eremina, V., Sood, M., Haigh, J., Nagy, A., Lajoie, G., Ferrara, N. et al. (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal disease. J Clin Invest111: 707-716.
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O’Shea, K.S. et al. (2006) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature380: 439-442.
23.
Ferrara, N. and Davis-Smith, T. ( 1997) The biology of vascular endothelial growth factor. Endocrine Rev18: 4-25.
24.
Finkenzeller, G., Wendel, K., Zimmermann, W., Westin, G. and Marmé, D. ( 2004) Activated Neu/ ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp1. Angiogenesis7: 59-68.
25.
Foekens, J.A., Peters, H.A., Grebenchtchiklov, N., Look, M.F., Meijer-Van Gelder, M.E., Geerts-Moespot, A. et al. (2001) High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer . Cancer Res61: 5407-5414.
26.
Forero, A., Saleh, M., Galleshaw, J., Jones, C., Shah, J., Percent, I. et al. (2009) A pilot trial of pre-operative (neoadjuvant) letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed estrogen and/or progesterone receptor positive breast cancer. Cancer Res69(Suppl.): 24s (Abstract #1088).
27.
Frangié, C., Lefaucheur, C., Medioni, J., Jacquot, C., Hill, G.S. and Nochy, D. ( 2007) Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol8: 177-178.
28.
García-Sáenz, J.A. , Martín, M., Calles, A., Bueno, C., Rodriguez, L., Bobokova, J. et al. (2008) Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer. J Chemother20: 632-639.
29.
Gordon, M.S., Margolin, K., Talpaz, M., Sledge, G.W., Holmgren, E., Benjamin, R. et al. (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol19: 843-850.
30.
Guardino, A.E., Chen, M., Levy, M. and Chen, M. ( 2009) Phase II trial with gemcitabine, paclitaxel and bevacizumab for the first-line treatment of metastatic breast cancer. Cancer Res69: 853s (Abstract 6089).
31.
Guarneri, V., Miles, D., Robert, N.J., Dieras, V.C., Glaspy, J., Smith, I.E. et al. (2009) Analysis of bevacizumab (Bev) therapy, bisphosphonate use and osteonecrosis of the jaw (ONJ) in >1900 patients treated in two randomized, controlled trials. Cancer Res69(Suppl.): 512s (Abstract #208).
32.
Guidi, A.J., Schnitt, S.J., Fisher, L., Tognazzi, K., Harris, J.R., Dvorak, H.F. et al. (1997) Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer80: 1945-1954.
33.
Herrlinger, U., Wiendl, H., Renninger, M., Förschler, H., Dichgans, J. and Weller, M. ( 2004) Vascular endothelial growth factor in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer91: 219-224.
34.
Hurvitz, S.A., Pegram, M.D., Lin, L.-S., Chan, D.S., Allen, H.J., Dichmann, R.A. et al. (2009) Final results of a Phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer. Cancer Res24(Suppl.): 854s (Abstract #6094).
35.
Hyder, S.M. ( 2006) Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocrine-related Cancer13: 667-687.
36.
Hyder, S.M., Nawaz, Z., Chiapetta, C. and Stancel, G.M. ( 2000) Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res60: 3183-3190.
37.
Izzidine, H., Brocheriou, I., Deray, G. and Rixe, O. ( 2007) Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant24: 682-685.
38.
Jensen, H.M., Chen, I., Devault, M.R. and Lewis, A.E. ( 1982) Angiogenesis induced by normal human breast tissue: a probable marker for precancer. Science218: 293-295.
39.
Kamba, T. and McDonald, D.M. ( 2007) Mechanisms of adverse effects of anti-VEGF therapy in cancer. Br J Cancer96: 1788-1795.
40.
Kowanetz, M. and Ferrara, N. ( 2006) Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res12: 5018-5022.
41.
Laugner, E., Taghavi, P., Chiles, K., Mahon, P.C. and Semenza, G.L. ( 2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol21: 3995-4004.
42.
Liang, Y., Brekken, R.A. and Hyder, S.M. ( 2006) Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones . Endocrine-Related Cancer13: 905-919.
43.
Lin, E.Y. and Pollard, J.W. ( 2007) Tumor associated macrophages press the angiogenic switch in breast cancer. Cancer Res67: 5064-5066.
44.
Linderholm, B., Andersson, J., Lindh, B., Beckman, L., Erlanson, M., Edin, K. et al. (2004) Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic therapy. Eur J Cancer40: 33-42.
45.
Linderholm, B., Tavelin, B., Grankvist, K. and Henriksson, R. ( 1998) Vascular endothelial growth factor is of high prognostic significance in node negative breast carcinoma. J Clin Oncol16: 3121-3128.
46.
Lohela, M., Bry, M., Tammela, T. and Alitalo, K.(2009) VEGFs and receptors in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol21: 154-165.
47.
Makhoul, I., Vicki, K.S., Korourian, S., Henry-Tillman, R.S., Siegel, E.R., Westbrook, K.C. et al. (2009) Bevacizumab combined with chemotherapy significantly improves pathologic complete response in patients with operable or locally advanced breast cancer. Cancer Res69(Suppl.): 343s (Abstract #5114).
48.
Margolin, K., Gordon, M.S., Holmgren, E., Gaudreault, J., Novotny, W., Fyfe, G. et al. (2001) Phase Ib trial of intravenous recombinant growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol19: 851-856.
49.
Masood, R., Cal, J., Zheng, T., Smith, D.L., Hinton, D.R. and Gill, P.S. ( 2001) Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood98: 1904-1913.
50.
Mayer, E.L., Kozloff, M., Qamar, R., Klencke, B., Balkissoon, J., Parmar, H. et al. (2009) SABRE-B: a randomized phase II trial evaluating the safety and efficacy of combining sunitinib with paclitaxel + bevacizumab as first-line treatment for HER2-negative metastatic breast cancer (MBC): final results. Cancer Res69(Suppl.): 245s (Abstract #3126).
51.
Miles, D., Chan, A., Dirix, L.Y., Cortés, J., Pivot, X., Piotr Tomczak, P. et al. (2010) Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol, DOI: 10.1200/JCO.2008.21.6457.
52.
Miller, K.D., Chap, L.I., Holmes, F.A., Cobleigh, M.A., Marcon, P.K., Fehrenbach, L. et al. (2005) Randomized phase III trial of capecitabine compared with bevacizumab and capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol23: 792-799.
53.
Miller, K.D., O’Neill, A., Perez, E.A., Seidman, A.D. and Sledge, G.W. ( 2007a) Phase II feasibility trial incorporating bevacizumab into dose dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial of the Eastern Cooperative Oncology Group (E2104). Breast Cancer Res Treat106(Suppl. 1): S147 (Abstract 3063).
54.
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E.A. et al. (2007b) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med357: 2666-2676.
55.
Perez, E.A., Hillman, D.W., Dentchev, T., Le-Lindqwister, N.A., Geeraerts, L.H., Fitch, T.R. et al. (2010) North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Ann Oncol21: 269-274.
56.
Perez-Atayde, A.R., Sallan, S.E., Tedrow, U., Connors, S., Allred, E. and Folkman, J. ( 1997) Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol150: 815-821.
57.
Presta, L.G., Chen, H., O’Connor, S.J., Chisholm, V., Meng, Y.G., Krummen, L. et al. (1997) Humanization of anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders . Can Res57: 4593-4599.
58.
Ramaswamy, B., Elias, A.D., Kelbick, N.T., Dodley, A., Morrow, M., Hauger, M. et al. (2006) Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res12: 3124-3129.
59.
Robert, N., Dieras, V., Glaspy, J., Brufsky, A., Bondarenko, I.N., Lipatov, O. et al. (2009) Clinical benefit rate and time to response in RIBBON-1, a randomized, double-blind, phase III trial of chemotherapy with or without bevacizumab(b) for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). Cancer Res69(Suppl.): 851s(Abstract #6085).
60.
Rochlitz, C., von Moos, R., Mannhart-Harms, M., Winterhalder, R., Rauch, D., Müller, A. et al. (2009) Pegylated liposomal doxorubicin and bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Eur J Cancer Suppl7: 266 (Abstract 5019).
61.
Ryan, P.D., Tung, N.M., Isakoff, S.J., Golshan, M., Richardson, A., Corben, A.D. et al. (2009) Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. J Clin Oncol27(Suppl.): 18s (Abstract 551).
62.
Ryden, L., Jirstrom, K., Bendahl, P.-A., Ferno, M., Nordenskjold, B. et al. (2005) Tumor-specific expression of vascular endothelial growth factor 2 but not vascular endothelial growth factor or human vascular endothelial growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol23: 4695-4704.
63.
Smith, I.E., Biganzoli, L., Cortes-Funes, H., Stroyakovskiy, D., Franke, F.A., Chlistalla, A. et al. (2009) Primary analysis of study MO19391, a 2000-patient open-label safety study of bevacizumab plus taxane-based therapy as first-line treatment of patients with locally recurrent or metastatic breast cancer. Cancer Res69(Suppl.): 292s (Abstract #4118).
64.
Tan, W.W., Dueck, A.C., Flynn, P., Steen, P., Anderson, D., Rowland, K. et al. (2009) Phase II Trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group Trial. Cancer Res69(Suppl.): 738s (Abstract #4096).
65.
Toi, M., Matumoto, T. and Bando, H. ( 2001) Vascular endothelial growth factor: its prognostic, predictive and therapeutic implications. Lancet Oncol2: 667-673.
66.
Traina, T.A., Rugo, H.S., Caravelli, J.F., Patil, S., Yeh, B., Melisko, M.E. et al. (2010) Feasibility of Letrozole with bevacizumab in patients with metastatic breast cancer. J Clin Oncol28: 628-633.
67.
Trinh, B., Van Dam, P., Prové, A., Maes, H., Van Laere, S., Tjalma, W. et al. (2009) Angiogenic escape and tumour progression in two patients with metastatic breast cancer receiving bevacizumab treatment . Cancer Res69(Suppl.): 112s (Abstract #1029).
68.
Vermeulen, P.B., Colpaert, C., Salgado, R., Royers, R., Hellemans, H., Van Den Heuvel, E. et al. (2001) Liver metastases from colorectal adenocarcinoma grow in three patterns with different angiogenesis and desmoplasia. J Pathol195: 336-342.
69.
Vermeulen, P.B., Gasparini, G., Fox, S.B., Colpaert, C., Marson, L.P., Gion, M. et al. (2002) Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours . Eur J Cancer38: 1564-1579.
70.
Wang, Y., Fei, D., Vanderlaan, M. and Song, A. ( 2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in-vitro. Angiogenesis7: 335-345.
71.
Wedam, S.B., Low, J.A., Yang, S.X., Chow, C.K., Choyke, P., Danforth, D. et al. (2006) Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol24: 769-777.
72.
Weidner, N., Folkman, J., Pozza, F., Bevilacque, P., Allred, E.N., Moore, D.H. et al. (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst84: 1875-1887.
73.
Weigand, M., Hantel, P., Kreienberg, R. and Waltenberger, J. ( 2005) Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis8: 197-204.
74.
Yang, S.X., Steinberg, S.M., Nguyen, D., Du, T.D., Modrusan, Z. and Swain, S.M. ( 2008) Gene expression profile and angiogenic markers correlate with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res14: 5893-5899.
75.
Zhu, X., Wu, S., Dahut, W.L. and Parikh, C.R. ( 2007) Risks for proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis49: 186-193.
